TABLE 3.
Logistic regression predicting radiation receipt for patients undergoing lumpectomy (N = 89,580; events = 59,331) for select women with breast cancer in the SEER database from 2004–2015
| OR (95% CI) | p value | Overall p value | |
|---|---|---|---|
| Diagnosis | < 0.001 | ||
| DCISM | -REF- | ||
| DCIS | 0.57 (0.52–0.63) | < 0.001 | |
| T1a IDC | 1.04 (0.94–1.15) | 0.40 | |
| Grade | < 0.001 | ||
| 1 | -REF- | ||
| 2 | 1.27 (1.22–1.32) | < 0.001 | |
| 3 | 2.03 (1.94–2.13) | < 0.001 | |
| Unknown | 1.03 (0.98–1.09) | 0.21 | |
| ER status | < 0.001 | ||
| Positive | -REF- | ||
| Negative/borderline | 1.03 (0.97–1.10) | 0.35 | |
| Unknown | 0.55 (0.51–0.59) | < 0.001 | |
| PR status | < 0.001 | ||
| Positive | -REF- | ||
| Negative/borderline | 1.12 (1.07–1.18) | < 0.001 | |
| Unknown | 0.81 (0.75–0.87) | < 0.001 | |
| HER2 status | < 0.001 | ||
| Positive | -REF- | ||
| Negative/borderline | 1.20 (1.09–1.32) | < 0.001 | |
| Unknown | 0.99 (0.70–1.08) | 0.77 | |
| Diagnosed before 2010* | 1.18 (1.07–1.29) | < 0.001 |
Patients with unknown radiation receipt were combined with those not receiving radiation therapy. Model adjusted for patient age, race/ethnicity, insurance status, and history of other cancers. DCIS ductal carcinoma in situ; DCISM DCIS with microinvasion; IDC invasive ductal carcinoma; ER estrogen receptor; PR progesterone receptor; HER2 human-epidermal-growth-factor-receptor-2
*
Patients diagnosed before 2010 did not routinely have HER2 status reported in the database